

# Summary table

Tables include all 477 participants

Table 1 demo

	data (N = 477)	Success (N = 277)	Failure (N = 200)
<b>Age</b>			
mean (sd)	28.32 ± 25.32	25.69 ± 24.28	31.95 ± 26.32
Range	1-94	1-89	1-94
NA	0(0%)	0(0%)	0(0%)
<b>Age Group</b>			
0-17y	229 (48.01%)	144 (51.99%)	85 (42.50%)
18y - 60 y	175 (36.69%)	100 (36.10%)	75 (37.50%)
>60 y	73 (15.30%)	33 (11.91%)	40 (20.00%)
<b>Gender</b>			
Female	207 (43.40%)	122 (44.04%)	85 (42.50%)
Male	270 (56.60%)	155 (55.96%)	115 (57.50%)
<b>Race</b>			
Black	201 (42.14%)	108 (38.99%)	93 (46.50%)
White	208 (43.61%)	127 (45.85%)	81 (40.50%)
Asian	18 (3.77%)	11 (3.97%)	7 (3.50%)
Other	14 (2.94%)	9 (3.25%)	5 (2.50%)
Unknown	36 (7.55%)	22 (7.94%)	14 (7.00%)
<b>Ethnicity</b>			
Hispanic	77 (16.14%)	50 (18.05%)	27 (13.50%)
Non-Hispanic	400 (83.86%)	227 (81.95%)	173 (86.50%)
<b>Home antiepileptic medications</b>			
0	118 (24.74%)	63 (22.74%)	55 (27.50%)
1	143 (29.98%)	87 (31.41%)	56 (28.00%)
2	112 (23.48%)	69 (24.91%)	43 (21.50%)

	data (N = 477)	Success (N = 277)	Failure (N = 200)
3	55 (11.53%)	33 (11.91%)	22 (11.00%)
4	28 (5.87%)	14 (5.05%)	14 (7.00%)
5	15 (3.14%)	9 (3.25%)	6 (3.00%)
6	6 (1.26%)	2 (0.72%)	4 (2.00%)
<b>History of epilepsy</b>			
Yes	343 (72.21%)	205 (74.28%)	138 (69.35%)
No	132 (27.79%)	71 (25.72%)	61 (30.65%)
NA	2(0.42%)	1(0.21%)	1(0.21%)
<b>Median duration of seizure</b>			
mean (sd)	75.78 ± 58.48	73.92 ± 59.88	78.34 ± 56.56
Range	6-620	6-620	9-385
NA	44(9.22%)	26(5.45%)	18(3.77%)
<b>Benzodiazepines given before ED arrival</b>			
Yes	218 (56.92%)	125 (56.82%)	93 (57.06%)
No	165 (43.08%)	95 (43.18%)	70 (42.94%)
NA	94(19.71%)	57(11.95%)	37(7.76%)
<b>Number of benzo doses</b>			
mean (sd)	2.55 ± 1.03	2.48 ± 1.00	2.64 ± 1.07
Range	1-9	1-8	1-9
NA	0(0%)	0(0%)	0(0%)
<b>Interval between 1st dose of benzo and administration of the study drug</b>			
mean (sd)	50.47 ± 62.94	51.09 ± 71.30	49.62 ± 49.22
Range	5-857	5-857	6-360
NA	0(0%)	0(0%)	0(0%)

## Table 2 Seizure types

	Success.A (N = 105)	Success.B (N = 83)	Success.C (N = 89)	Failure.A (N = 74)	Failure.B (N = 66)	Failure.C (N = 60)
<b>Seizure Type</b>						

	<b>Success.A (N = 105)</b>	<b>Success.B (N = 83)</b>	<b>Success.C (N = 89)</b>	<b>Failure.A (N = 74)</b>	<b>Failure.B (N = 66)</b>	<b>Failure.C (N = 60)</b>
Stroke	3 (2.86%)	4 (4.82%)	1 (1.12%)	3 (4.05%)	4 (6.06%)	2 (3.33%)
Electrolyte anomalies	2 (1.90%)	0 (0.00%)	0 (0.00%)	1 (1.35%)	2 (3.03%)	1 (1.67%)
CNS Tumors/CNS infection	1 (0.95%)	3 (3.61%)	0 (0.00%)	4 (5.41%)	2 (3.03%)	5 (8.33%)
Unprovoked	39 (37.14%)	26 (31.33%)	31 (34.83%)	25 (33.78%)	31 (46.97%)	14 (23.33%)
Anti-epileptic drug withdrawal/non compliance	14 (13.33%)	12 (14.46%)	16 (17.98%)	10 (13.51%)	5 (7.58%)	4 (6.67%)
Febrile illness	23 (21.90%)	16 (19.28%)	21 (23.60%)	10 (13.51%)	9 (13.64%)	15 (25.00%)
Insufficient information to determine/idiopathic/cryptogenic	0 (0.00%)	2 (2.41%)	5 (5.62%)	9 (12.16%)	1 (1.52%)	4 (6.67%)
Toxic (alcohol / drug withdrawal-not AEDs, poisoning, etc.)	6 (5.71%)	5 (6.02%)	3 (3.37%)	7 (9.46%)	4 (6.06%)	5 (8.33%)
Other	17 (16.19%)	15 (18.07%)	12 (13.48%)	5 (6.76%)	8 (12.12%)	10 (16.67%)

## Plot